ZNTL (STOCKS)
Zentalis Pharmaceuticals, Inc. Common Stock
$5.570000
-1.040000 (-15.73%)
Prev close: $6.610000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Julia Marie Eastland
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $395.09M
- Employees
- 166
- P/E (TTM)
- -3.46
- P/B (TTM)
- 2.11
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $152.81M |
| Research and Development | $107.30M |
| Other Operating Expenses | $45.51M |
| Operating Income/Loss | -$152.81M |
| Income/Loss Before Equity Method Investments | -$136.62M |
| Income/Loss From Continuing Operations After Tax | -$137.06M |
| Income/Loss From Continuing Operations Before Tax | -$136.62M |
| Income/Loss From Equity Method Investments | $0.00 |
| Income Tax Expense/Benefit | $442.00K |
| Income Tax Expense/Benefit, Current | $391.00K |
| Income Tax Expense/Benefit, Deferred | $51.00K |
| Net Income/Loss | -$137.06M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$137.06M |
| Net Income/Loss Available To Common Stockholders, Basic | -$137.06M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.91 |
| Diluted Earnings Per Share | -$1.91 |
| Basic Average Shares | 71,869,000 |
| Diluted Average Shares | 71,869,000 |
| Assets | $288.97M |
| Current Assets | $253.19M |
| Noncurrent Assets | $35.78M |
| Fixed Assets | $2.77M |
| Other Non-current Assets | $33.01M |
| Liabilities | $72.76M |
| Current Liabilities | $36.56M |
| Accounts Payable | $7.21M |
| Wages | $9.78M |
| Other Current Liabilities | $19.57M |
| Noncurrent Liabilities | $36.20M |
| Equity | $216.20M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $216.20M |
| Liabilities And Equity | $288.97M |
| Net Cash Flow From Operating Activities | -$125.25M |
| Net Cash Flow From Operating Activities, Continuing | -$125.25M |
| Net Cash Flow From Investing Activities | $131.62M |
| Net Cash Flow From Investing Activities, Continuing | $131.62M |
| Net Cash Flow From Financing Activities | -$4.28M |
| Net Cash Flow From Financing Activities, Continuing | -$4.28M |
| Net Cash Flow | $2.09M |
| Net Cash Flow, Continuing | $2.09M |
| Comprehensive Income/Loss | -$137.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$137.42M |
| Other Comprehensive Income/Loss | -$362.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$362.00K |